Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Lee's Pharm In-licenses Second Product from Italy's Abiogen

publication date: Sep 8, 2014
Lee's Pharm in-licensed China rights to distribute a second prescription drug product from Abiogen Pharma of Italy. In the latest deal, Lee's will market Thorens® Cholecalciferol (vitamin D3) in mainland China, Hong Kong, Macau and Taiwan. Earlier this year, Lee's gained China rights to Abioden's Attila®, an orphan drug for brittle bone disease (see story). Vitamin D deficiency is a common cause of osteoporosis, especially in dialysis patients, whose kidneys often cannot process the vitamin. More details....

Stock Symbol: (HK: 950)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital